Timing is everything: new trial aims to reduce transplant complications by adjusting when stem cells are given
NCT ID NCT07047456
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial is testing whether changing the timing of stem cell infusion after a single umbilical cord blood transplant can lower the risk of severe acute graft-versus-host disease (aGVHD) in people with blood cancers. The study will enroll 134 participants who are in remission and receiving their first cord blood transplant. Researchers will compare different infusion times to see which leads to fewer severe aGVHD cases in the first 100 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
umbilical cord blood stem cells
What this could lead to
If successful, this could establish a simple timing strategy to lower the risk of severe graft-versus-host disease after cord blood transplants.
What could go wrong
This is a single-center trial with 134 participants, so results may not apply broadly. The intervention is a procedural change, not a new drug, so the impact may be modest.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital
RECRUITINGHefei, Anhui, 230001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••